SMN2 and proximal spinal muscular atrophy: This would suggest that there are additional genetic modifiers of SMA disease severity aside from SMN2. It is important to identify and characterize these novel modifiers for the development of new SMA biomarkers and targets for the development of therapeutic strategies for SMA [218].